An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.
Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.
By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...
Moderna posts a narrower-than-anticipated loss and sharply higher revenue for the first quarter.
COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...
CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...
After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.
The first shipments of the Moderna vaccine for COVID-19 are being deployed to First Nations in Manitoba. Beginning Thursday, the province will ship 5,300 doses of the vaccine to various communities to ...
Moderna surpassed Wall Street estimates for first-quarter revenue on Friday, helped by better-than-expected sales of its COVID-19 vaccine in international markets, sending its shares up nearly 5% in ...
Moderna is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ...
Stocktwits on MSN
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again
Novavax posted Q1 revenue of $139.5 million, above analysts’ estimate of $78.3 million, helped by licensing agreements. ・The drugmaker also said that patients who received Nuvaxovid were “twice as ...
Pfizer (NYSE:PFE | PFE Price Prediction) and Moderna (NASDAQ:MRNA) just closed the books on Q4 2025, and the contrast is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results